Company news
Immutep Ltd (ASX:IMM) news
Immutep Ltd news releases on 6ix. Latest, Nov 9, 2023: Immutep Completes Enrolment for TACTI-003 Phase IIb Trial
Press releases — page 3
Immutep Completes Enrolment for TACTI-003 Phase IIb Trial
November 8, 2023
Lead-in phase completed for ph2/3 trial in Breast Cancer
November 5, 2023
New Biomarker Data from TACTI-002 trial in 1st line NSCLC
November 2, 2023
Immutep reports promising data from INSIGHT-003 trial
October 23, 2023
Webcast slides for new Efti clinical data in 1st line NSCLC
October 22, 2023
Excellent Overall Survival in Non-Small Cell Lung Cancer
October 22, 2023
Immutep announces publication of ESMO 2023 abstracts
October 15, 2023
Commercial Scale Manufacturing of Efti for Clinical Trials
September 20, 2023
Appendix 4E & 2023 Full Year Statutory Accounts
August 29, 2023
Immutep receives positive scientific advice from EMA
August 1, 2023
1st Patient Dosed in Phase 2 Soft Tissue Sarcoma Trial
July 27, 2023
US patent granted for Efti with PD-1 pathway inhibitor
June 27, 2023
Immutep granted US patent for IMP761 agonist LAG-3 antibody
June 20, 2023
A$80 million fully underwritten equity raising
May 30, 2023
Charles River Laboratories to run IMP761 Toxicology Study
May 28, 2023
Publication of Abstracts for ASCO 2023 Annual Meeting
May 25, 2023
1st patient dosed in AIPAC-003 ph2/3 breast cancer trial
May 24, 2023
Promising New Data in 1st line NSCLC from INSIGHT-003 Trial
May 23, 2023
Excellent initial Overall Survival Benefit in 1st line NSCLC
May 16, 2023
FDA supportive of Efti registrational trial in lung cancer
May 15, 2023
Approval to start Efti & Bavencio trial in urothelial cancer
April 30, 2023
Immutep to announce new TACTI-002 data at ASCO 2023
April 26, 2023
Response to ASX Aware Query
April 18, 2023
Initiation of Phase 2 Trial for Efti in Soft Tissue Sarcoma
April 16, 2023
Positive Final Data in 2nd Line Metastatic NSCLC Patients
March 31, 2023
Expansion of INSIGHT-003 trial for Efti in 1st Line NSCLC
March 29, 2023
Initiation of Ph 2/3 Trial for Metastatic Breast Cancer
March 13, 2023
Enrolment Target Reached for INSIGHT-003 Trial in NSCLC
February 5, 2023
TACTI-003 trial 50% enrolment milestone has been achieved
January 3, 2023
Update on MBC trial design following successful FDA meeting
December 23, 2022
Commercial Scale in Manufacturing of Efti Achieved
December 7, 2022
GMP Manufacturing Process Developed for IMP761 LAG-3 Agonist
December 5, 2022
Immutep enters 2nd collaboration with Pfizer and Merck KGaA
November 28, 2022
Immutep receives A$1 million R&D Tax Incentive
November 13, 2022
Immutep Webcast to discuss clinical data presented at SITC
November 10, 2022
New Patents Granted in Japan and South Korea for Efti
November 9, 2022
Late Breaking Abstract accepted for SITC Oral Presentation
November 2, 2022
Independent DMC recommends to continue TACTI-003 as planned
October 25, 2022
Abstracts accepted for Presentation at SITC 2022
October 5, 2022
Fast Track granted by US FDA for Efti in 1st line NSCLC
October 3, 2022
Immutep Receives A$2.7 million R&D French Tax Incentive
September 22, 2022
Clinical Development Update for Eftilagimod Alpha
September 13, 2022
New investigator-initiated ph2 trial in Soft Tissue Sarcoma
September 5, 2022
Appendix 4E & 2022 Full Year Statutory Accounts
August 31, 2022
Japanese Patent Grant for efti, soluble LAG-3 with anti-PD-1
August 30, 2022
TACTI-002 2nd line lung cancer data presented at 2022 WCLC
July 31, 2022
Quarterly Activities/Appendix 4C Cash Flow Report
July 28, 2022
Immutep granted Japanese Patent for IMP761
July 5, 2022
Webcast slides for 1st line NSCLC data from TACTI-002 trial
June 5, 2022
Immutep announces publication of ASCO 2022 abstracts
May 26, 2022